Novamab
Latest round
- Series B
Last raised
- Apr 2026
Total raised
- $101M
Investors
- 15
About Novamab
, trading as Novamab, , is a pharmaceutical company that focuses on the research and development of nano-antibody drugs. It has an R&D and production base of more than 7,500 square meters, as well as a camel breeding base, with nearly 90 employees. Yakun Wan, the founder, chairman, and CEO of the company, is the director of the Nano Antibody Engineering Technology R&D Center in Jiangsu Province. The company acquired 24 patents. In 2023, its inhaled TSLP nano-antibody drug LQ043H was approved for clinical trials in China. The company's business is inhaled nano-antibody drug research and development. It has technology platforms based on nano-antibodies, including a nanoantibody screening platform, a picrosystem CMC process development platform, and an inhalation macromolecule drug discovery and development platform. The company has pipelines in respiratory diseases, immune diseases, and tumors, such as LQ036, LQ043, LQ056, and LQ059. The company’s revenue is generated by providing innovative nano-antibody drugs.
Who invested in Novamab
15 investors across 5 rounds
See all investors in Novamab
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Novamab
Who invested in Novamab?
Novamab has 15 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Novamab raised?
Novamab has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Novamab last raise money?
Novamab's most recent round on record is a Series B, in Apr 2026.
What does Novamab do?
, trading as Novamab, , is a pharmaceutical company that focuses on the research and development of nano-antibody drugs.
Where is Novamab headquartered?
Novamab is headquartered in Shanghai, China.
Which VCs invest in companies like Novamab?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Novamab's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Novamab? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.